Shandong Lukang Pharmaceutical Group Saite Co., Ltd.

Primary objective: To study the relative bioavailability of dapagliflozin tablets 10 mg (test preparation) produced by Shandong Lukang Pharmaceutical Group Saite Co., Ltd. and original dapagliflozin tablets 10 mg (FORXIGA/Andatang, reference preparation) of AstraZeneca AB as the licensee in healthy subjects in the fasting/postprandial state, and to evaluate the bioequivalence between the test preparation and the reference preparation. Secondary objective: To observe the safety and tolerability of the test preparation and the reference preparation in healthy Chinese subjects through changes in adverse event incidence, laboratory test results, vital signs and physical examinations.

Main purpose: This study used finasteride tablets developed by Shandong Lukang Pharmaceutical Group Saite Co., Ltd. as the test preparation. According to the relevant regulations of bioequivalence tests, Proscar licensed by Organon Pharma (UK) Limited was used as the reference preparation. Human bioequivalence tests were conducted in fasting/postprandial states to evaluate the bioequivalence of the test preparation and the reference preparation in healthy male subjects. Secondary purpose: To observe the safety of the test preparation and the reference preparation in healthy male subjects.

To study the relative bioavailability of 0.25 g of azithromycin tablets produced by Shandong Lukang Pharmaceutical Group Saite Co., Ltd. (test preparation) and 0.25 g of azithromycin tablets produced by Pfizer Pharmaceuticals Co., Ltd. (Azithromycin Tablets®/Xisuomei, reference preparation) in healthy subjects under fasting and fed conditions, and to evaluate whether the test preparation and the reference preparation are bioequivalent.